Tomoko Y. Funazo
Kyoto, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.
Journal: Nature communications
Published: September 17, 2025
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.
Journal: Molecular and clinical oncology
Published: November 20, 2024
Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
Journal: BMC cancer
Published: July 05, 2024
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Journal: Molecular cancer therapeutics
Published: June 14, 2023
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Journal: Scientific reports
Published: February 07, 2023
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Journal: Oncology letters
Published: May 19, 2022
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Journal: Cancer science
Published: April 27, 2022
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 21, 2020
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
Journal: Molecular cancer therapeutics
Published: July 09, 2019
Last Updated: 09/26/2026